Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Online Letters: Comments and Responses

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Response to Woo and Eizirik

  1. David M. Nathan, MD and
  2. for the ADA/EASD Consensus Committee
  1. From the Diabetes Center, Massachusetts General Hospital, Boston, Massachusetts
  1. Corresponding author: David M. Nathan, dnathan{at}partners.org
Diabetes Care 2009 Mar; 32(3): e37-e38. https://doi.org/10.2337/dc08-2195
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Response to Woo and Eizirik

We appreciate Dr. Woo's response to our study (1) and his comparison (2) of the Canadian Diabetes Association (CDA) clinical practice guidelines and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus algorithm and welcome the opportunity to address the differences he has identified.

The original ADA/EASD consensus algorithm and the subsequent revisions were developed independently by the consensus group and were then presented to the two major diabetes organizations for their review and approval of the process. Dr. Woo notes the CDA's process of data review with a “standardized evidence-based approach” and the participation of “over 90 authors and a steering committee of 18” and concludes that the process removed “as much bias as possible,” implying that this approach was superior to our consensus algorithm process. He further notes that the CDA committee “believes that patients and practitioners deserve more choices” and states, with no evidence provided, that “when basal insulin is used with an intermediate-acting insulin, it is very likely that more than one injection will be required.” These statements belie the objective methodologies cited by Dr. Woo.

More important, in our view, is the “equal weight” that CDA gave to all pharmaceutical agents available in Canada. This even-handed approach, presumably to provide the flexibility that CDA believes is important, does not aid practitioners and patients. There are demonstrable differences between these medications in their effectiveness, side-effect profiles, tolerability, ease of use, and costs that were used in the development of our algorithm and that should influence clinicians. The example cited by Dr. Woo, in which he takes the algorithm to task for not recommending glyburide, is illustrative. Our consensus algorithm specifically recommends against using glyburide, despite its glucose-lowering effectiveness and low cost, because it has a higher risk for hypoglycemia than other similarly effective and low-cost sulfonylureas (3,4). In our opinion, this type of information is highly relevant and should inform health care providers and their patients as to which agents should be used. Our goal was to provide useful guidelines for the choice of medications from the many that are available.

Finally, even with the careful evidence-based review carried out by CDA, we must disagree with their conclusion that the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Veterans Affairs Diabetes Trial (VADT), and Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trials (5–7) have exonerated rosiglitazone of the safety concern raised in previous meta-analyses. The trials were not “specifically designed to help address this question,” despite the CDA's claim to the contrary. Only the RECORD study was designed to address the effects of rosiglitazone on cardiovascular disease outcome, and its interim analysis suggested a trend, albeit nonsignificant, for worse outcomes with rosiglitazone (7,8).

We agree with Dr. Eizirik's concern (9) regarding the potential for dualities of interest to influence the development of algorithms such as ours. This issue potentially affects all of academic medicine. In the current research environment, where academic investigators participate in company-supported trials, it is difficult to find individuals with the requisite expertise and experience who do not have dualities of interest. During the selection of the consensus group members and our deliberations, all of our dualities were considered and discussed openly. Although the results of the process do not directly address Dr. Eizirik's concern, we note with some irony that we have received far more complaints regarding our recommendations from the pharmaceutical industry than from individuals concerned with our potential conflicts. We hope that the stated rationale for our choices convinces readers that the algorithm was developed without the intrusion of any bias other than the shared bias of the consensus group to provide the best care for patients with type 2 diabetes.

Acknowledgments

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

  • DIABETES CARE

References

  1. ↵
    Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203, 2009
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Woo V: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes (Letter). Diabetes Care 32:e34, 2009. DOI:doi:10.2337/dc08-2093
    OpenUrlFREE Full Text
  3. ↵
    Holstein A, Plaschke A, Egberts E-H: Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473, 2001
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM: A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–394, 2007
    OpenUrlAbstract/FREE Full Text
  5. ↵
    The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559, 2008
    OpenUrlCrossRefPubMed
  6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, for the VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139, 2009
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, for the RECORD Study Group: Rosiglitazone evaluated for cardiac outcomes—an interim analysis. N Engl J Med 357:28–38, 2007
    OpenUrlCrossRefPubMed
  8. ↵
    Nathan DM: Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 357:64–66, 2007
    OpenUrlCrossRefPubMed
  9. ↵
    Eizirik DL: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes (Letter). Diabetes Care 32:e35, 2009. DOI:doi:10.2337/dc08-2275
    OpenUrlFREE Full Text
PreviousNext
Back to top
Diabetes Care: 32 (3)

In this Issue

March 2009, 32(3)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan
Diabetes Care Mar 2009, 32 (3) e37-e38; DOI: 10.2337/dc08-2195

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan
Diabetes Care Mar 2009, 32 (3) e37-e38; DOI: 10.2337/dc08-2195
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417
  • Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417
  • Comment on Lázaro-Martínez et al. Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial. Diabetes Care 2014;37:789–795
Show more Online Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.